ロード中...
Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
PURPOSE: There is evidence from nonrandomized studies that a proportion of ipilimumab-treated patients with advanced melanoma experience long-term survival. To demonstrate a long-term survival benefit with ipilimumab, we evaluated the 5-year survival rates of patients treated in a randomized, contro...
保存先:
| 出版年: | J Clin Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Clinical Oncology
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5795709/ https://ncbi.nlm.nih.gov/pubmed/25713437 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.56.6018 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|